SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
A phase 3 trial of Trastuzumab duocarmazine, Lapatinib, Capecitabine, Trastuzumab, Vinorelbine and Eribulin in Breast cancer, run by Byondis B.V., completed.
Overview
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT03262935 by Byondis B.V., with 437 participants recorded, started 2017-12-15 and reaching its primary completion in 2021-03-31. Interventions recorded: (vic-)trastuzumab duocarmazine, Physician's choice. Conditions recorded: Metastatic Breast Cancer.
Linked to the drug Trastuzumab duocarmazine because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialSYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
Shares Byondis, Trastuzumab duocarmazine and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
- TrialStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
- TrialASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine, Trastuzumab and the tag pipeline.
- TrialAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
- TrialA Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
Shares Lapatinib, Capecitabine and the tag pipeline.
- TrialA Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
- TrialRC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
Shares Capecitabine, Breast cancer (all types), Trastuzumab and the tag pipeline.